3085. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
作者: Paul E Sax.;David Wohl.;Michael T Yin.;Frank Post.;Edwin DeJesus.;Michael Saag.;Anton Pozniak.;Melanie Thompson.;Daniel Podzamczer.;Jean Michel Molina.;Shinichi Oka.;Ellen Koenig.;Benoit Trottier.;Jaime Andrade-Villanueva.;Gordon Crofoot.;Joseph M Custodio.;Andrew Plummer.;Lijie Zhong.;Huyen Cao.;Hal Martin.;Christian Callebaut.;Andrew K Cheng.;Marshall W Fordyce.;Scott McCallister.; .
来源: Lancet. 2015年385卷9987期2606-15页
Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug with a 90% reduction in plasma tenofovir concentrations. Tenofovir alafenamide-containing regimens can have improved renal and bone safety compared with tenofovir disoproxil fumarate-containing regimens.
|